Dr. Albert Dahan
Anesthesiology at Leiden University Medical Center
Biography & Research Background
Albert Dahan, MD, PhD, is a Professor of Anesthesiology at Leiden University Medical Center (LUMC), The Netherlands. Dr. Dahan is a key clinical investigator who identified the unmet medical need of painful neuropathy in sarcoidosis study subjects and initiated the pivotal clinical trials testing ARA-290 for this condition, including the NERVARA Trial (NCT02039687). His work demonstrated that ARA-290 improved symptoms of small fiber neuropathy, increased corneal nerve fiber density, and enhanced quality of life in study subjects with sarcoidosis and type 2 diabetes. He is the lead author on several foundational ARA-290 clinical publications in Molecular research compound. Albert Dahan is being referenced as one of the leading scientists involved in the research and development of ARA-290. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure US Peptide and this doctor.
External Profiles
Authored Research Profiles (1)
Dr. Albert Dahan is referenced as a leading researcher in the following peptide research profiles on Pure U.S. Peptides:
Dr. Albert Dahan is being referenced as one of the leading scientists involved in the research and development of the peptides listed above. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of any product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure U.S. Peptides and this researcher. The purpose of citing the researcher is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying these peptides.